Enliven Therapeutics (ELVN) Free Cash Flow (QoQ) (2019 - 2026)
Enliven Therapeutics (ELVN) Free Cash Flow (QoQ) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.11 Bn | 463.32 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.48 Bn | 115.23 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.55 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - |
| 8 | Argenx Se | 55.66 Bn | 50.47 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.42 Bn | 34.41 Bn | 959.66 Mn |
| 10 | Enliven Therapeutics | 3.40 Bn | 2.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.80% |
| Dec 31, 2025 | -19.28% |
| Sep 30, 2025 | 22.78% |
| Jun 30, 2025 | 28.79% |
| Mar 31, 2025 | -40.37% |
| Dec 31, 2024 | -40.85% |
| Sep 30, 2024 | 40.24% |
| Jun 30, 2024 | 12.59% |
| Mar 31, 2024 | -87.11% |
| Dec 31, 2023 | 21.46% |
| Sep 30, 2023 | -31.09% |
| Jun 30, 2023 | 41.86% |
| Mar 31, 2023 | -153.15% |
| Dec 31, 2022 | -27.63% |
| Sep 30, 2022 | 13.01% |
| Jun 30, 2022 | 29.64% |
| Mar 31, 2022 | 15.46% |
| Dec 31, 2021 | -14.53% |
| Sep 30, 2021 | -5.17% |
| Jun 30, 2021 | 20.47% |